Benzinga | Dec 9, 2021 09:47PM EST

Wells Fargo Initiates Coverage On Regeneron Pharmaceuticals with Overweight Rating, Announces Price Target of $750

Wells Fargo analyst Mohit Bansal initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight rating and announces Price Target of $750.